BlackRock Institutional Trust Company, N.A. - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 14 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BlackRock Institutional Trust Company, N.A. ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2016$17,000
-26.1%
7,686
-7.8%
0.00%
Q2 2016$23,000
-30.3%
8,334
-27.2%
0.00%
Q1 2016$33,000
-42.1%
11,449
-12.6%
0.00%
Q4 2015$57,000
-43.0%
13,1000.0%0.00%
Q3 2015$100,000
-31.5%
13,1000.0%0.00%
Q2 2015$146,00013,1000.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q4 2016
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 535,590$2,705,0001.58%
Millrace Asset Group, Inc. 200,000$1,010,0000.79%
Private Wealth Partners, LLC 1,000,000$5,050,0000.77%
PERKINS CAPITAL MANAGEMENT INC 249,700$1,261,0000.76%
Timpani Capital Management LLC 206,119$1,041,0000.30%
Diametric Capital, LP 64,329$325,0000.28%
Granahan Investment Management 941,170$4,753,0000.26%
Kalos Management, Inc. 69,900$308,0000.16%
SYMMETRY PEAK MANAGEMENT LLC 85,000$429,0000.15%
B. Riley Wealth Advisors, Inc. 250,000$1,263,0000.15%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders